公开(公告)号：US09259390B2

公开(公告)日：2016-02-16

申请号：US12220374

申请日：2008-07-24

申请人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

发明人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

IPC分类号： A61K31/4184 ,  A61K9/107 ,  A61K9/00

CPC分类号： A61K9/1075 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/4184

摘要： Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%.

公开(公告)号：US20140142251A1

公开(公告)日：2014-05-22

申请号：US14131152

申请日：2012-07-04

申请人： Dong Liang ,  Weihua Ye ,  Yong Lu ,  Zhen Tong ,  Zhaohui Chen

发明人： Dong Liang ,  Weihua Ye ,  Yong Lu ,  Zhen Tong ,  Zhaohui Chen

IPC分类号： C08L9/06

摘要： The present invention relates to a method for producing a filled elastomer wherein a rubber composition is produced by mixing I) raw rubber, II) cross linking agent, III) filler, IV) isocyanate terminated polymer composition and optionally V) further additives and cross linking of the rubber composition. The present invention further relates to a filled elastomer obtainable according to said method and the use of filled elastomers according to the invention as shoe sole.

摘要翻译： 本发明涉及一种填充弹性体的制造方法，其中通过混合I）生橡胶，II）交联剂，III）填料，IV）异氰酸酯封端的聚合物组合物和任选的V）进一步添加和交联来制备橡胶组合物 的橡胶组合物。 本发明还涉及根据所述方法可获得的填充弹性体和根据本发明的填充弹性体作为鞋底的用途。

公开(公告)号：US20120289584A1

公开(公告)日：2012-11-15

申请号：US13320901

申请日：2010-05-16

申请人： Kunyuan Cui ,  Dong Liang ,  David Sweedler

发明人： Kunyuan Cui ,  Dong Liang ,  David Sweedler

IPC分类号： A61K31/7088 ,  C07H21/02 ,  A61P35/00 ,  A61P1/16 ,  A61P11/00 ,  C07H21/00 ,  C07H21/04

CPC分类号： C12N15/88 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1272 ,  A61K9/145 ,  A61K47/6911

摘要： This disclosure provides compositions that are useful combined with therapeutics, and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

摘要翻译： 本公开提供了与治疗学结合使用并且在疾病和病症的诊断和治疗中有用的组合物。 所述组合物可用于将诸如核酸治疗剂的试剂递送至细胞，组织，器官和受试者。

公开(公告)号：US20070293449A1

公开(公告)日：2007-12-20

申请号：US11766038

申请日：2007-06-20

申请人： Kunyuan Cui ,  Roger Adami ,  Dong Liang

发明人： Kunyuan Cui ,  Roger Adami ,  Dong Liang

IPC分类号： A61K48/00 ,  C12N15/88

CPC分类号： C12N15/87 ,  A61K9/1272

摘要： Pharmaceutical compositions and methods of use of a composition containing a double-stranded RNA (dsRNA), cationic lipids, non-cationic lipids, and lipophilic delivery-enhancing compounds.

摘要翻译： 含有双链RNA（dsRNA），阳离子脂质，非阳离子脂质和亲脂性递送增强化合物的组合物的药物组合物和方法。

公开(公告)号：US20050217476A1

公开(公告)日：2005-10-06

申请号：US11098483

申请日：2005-04-05

申请人： Dong Liang

发明人： Dong Liang

IPC分类号： B01L3/02 ,  F01B3/00 ,  G01N35/10

CPC分类号： G01N35/1011 ,  B01L3/021 ,  B01L2400/0487 ,  B01L2400/0633 ,  B01L2400/0666

摘要： Described here is a mechanical and electronic device which can accurately draw up and dispense a volume of fluid. A novel syringe is described which can replace (and overcome some of the shortfalls) of the traditional mechanical syringe by way of a liquid syringe. The syringe system is designed to be used in conjunction with modern liquid handling systems used in biological and biochemical research as related to drug screening. However, the syringe system is not limited to such applications. Also of key importance to this invention, is the use of a monitoring system to accurately monitor and record the actual volumes being drawn up and dispensed. The liquid piston has the advantage of reduced friction and removes the necessity for there to be any o-ring or sealing system which requires periodic replacement and/or maintenance.

摘要翻译： 这里描述的是可以精确地绘制和分配一定体积的流体的机械和电子装置。 描述了一种新颖的注射器，其可以通过液体注射器代替（并克服一些缺点）传统的机械注射器。 注射器系统设计用于与药物筛选相关的生物和生物化学研究中使用的现代液体处理系统。 然而，注射器系统不限于这种应用。 本发明的关键重点还在于使用监控系统来准确地监测和记录正在绘制和分配的实际体积。 液体活塞具有减小摩擦的优点，并且消除了需要定期更换和/或维护的任何O形环或密封系统的必要性。

公开(公告)号：US09233971B2

公开(公告)日：2016-01-12

申请号：US13819147

申请日：2011-08-26

申请人： Kunyuan Cui ,  Dong Liang

发明人： Kunyuan Cui ,  Dong Liang

IPC分类号： C07D487/22 ,  C07D257/02 ,  C07D255/02 ,  C07D259/00 ,  A61K47/48 ,  C12N15/87 ,  C07D295/13

CPC分类号： C07D487/22 ,  A61K47/544 ,  A61K47/549 ,  A61K47/55 ,  C07D255/02 ,  C07D257/02 ,  C07D259/00 ,  C07D295/13 ,  C12N15/87

摘要： What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: When substituents R and R′ that are hydrophobic substituents, the macrocyclic compound functions as a lipid and is compatible with lipid systems, including liposomes and lipid particles. When present in certain lipid systems, the macrocyclic compound enhances the ability of the lipid system to facilitate delivery of therapeutic molecules to target cells in a mammalian subject.

摘要翻译： 所描述的是通过含有胺的环状化合物与环氧化物反应形成的大环化合物。 大环化合物具有以下结构：当作为疏水取代基的取代基R和R'时，大环化合物起脂质的作用，并且与脂质体系（包括脂质体和脂质）相容。 当存在于某些脂质体系中时，大环化合物增强了脂质系统促进治疗分子向哺乳动物受试者中的靶细胞递送的能力。

公开(公告)号：US08293519B2

公开(公告)日：2012-10-23

申请号：US10566329

申请日：2003-08-13

申请人： Feijun Xian ,  Wanli Xing ,  Jing Cheng ,  Dong Liang ,  Liang Zhang ,  Dong Wang

发明人： Feijun Xian ,  Wanli Xing ,  Jing Cheng ,  Dong Liang ,  Liang Zhang ,  Dong Wang

IPC分类号： C12M1/36 ,  G01N15/06 ,  B01L3/00

CPC分类号： B01L3/50853 ,  B01J2219/00281 ,  B01J2219/00596 ,  B01J2219/00659 ,  B01L9/52 ,  B01L2200/0689 ,  B01L2300/0636 ,  B01L2300/0822 ,  C12Q1/6837 ,  C40B60/14 ,  G01N33/54366

摘要： This invention relates generally to the field of microarray chips and uses thereof. In particular, the invention provides a microarray reaction device that can be used in assaying the interaction between various moieties, e.g., nucleic acids, immunoreactions involving proteins, interactions between a protein and a nucleic acid, a ligand-receptor interaction, and small molecule and protein or nucleic acid interactions, etc. Articles of manufacture and kits comprising the microarray reaction device and assaying methods using the microarray reaction device are also provided.

摘要翻译： 本发明一般涉及微阵列芯片领域及其用途。 特别地，本发明提供一种微阵列反应装置，其可用于测定各种部分之间的相互作用，例如核酸，涉及蛋白质的免疫反应，蛋白质与核酸之间的相互作用，配体 - 受体相互作用和小分子，以及 蛋白质或核酸相互作用等。还提供了包含微阵列反应装置的生产制品和试剂盒以及使用微阵列反应装置的测定方法。

公开(公告)号：US20100310611A1

公开(公告)日：2010-12-09

申请号：US12802621

申请日：2010-06-10

申请人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

发明人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

IPC分类号： A61K31/4184 ,  A61K9/107 ,  A61P33/10 ,  A61P33/12

CPC分类号： A61K9/1075 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/4184

摘要： Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%.

摘要翻译： 本文提供了药物递送系统，例如适合于向对象的肠胃外或口服递送的自 - 纳米乳化药物递送系统，自乳化药物递送系统和胃肠外微乳剂制剂。 药物递送系统可以在微乳液制剂中包含苯并咪唑衍生物，例如甲苯达唑，油，表面活性剂，辅助表面活性剂和偶极非质子溶剂。 还提供了通过使用组合特定乳剂液滴直径的组合物和其中表面活性剂：助表面活性剂的比例来改善治疗病理生理状况期间苯并咪唑衍生物的生物利用度的方法，用于增加苯并咪唑衍生物在肺中的浓度和保留通过 具有约35nm至小于100nm的液滴尺寸的肠胃外可施用的微乳液，并且在通过具有表面活性剂的肠胃外可施用的微乳液的治疗性治疗期间限定苯并咪唑衍生物的溶血安全微乳液：辅助表面活性剂含量为约6％至48％ 。

公开(公告)号：US20100022618A1

公开(公告)日：2010-01-28

申请号：US12231900

申请日：2008-09-05

申请人： Dong Liang ,  David Sweedler ,  Kunyuan Cui

发明人： Dong Liang ,  David Sweedler ,  Kunyuan Cui

IPC分类号： A61K31/713 ,  C12N15/113

CPC分类号： C12N15/1138 ,  C12N15/111 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/341 ,  C12N2310/351 ,  C12N2310/51 ,  C12N2310/53 ,  C12N2310/531

摘要： Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.

摘要翻译： 长干扰核酸（iNA）双链体，其长度为至少30个核苷酸，其在反义或有义链中或正义链和反义链中具有至少一个切口或核苷酸间隙。 这些长的iNA双链体在转染哺乳动物细胞时不诱导干扰素反应。 反义链可以靶向两个单独的mRNA或两个片段的一个mRNA。

公开(公告)号：US20090048322A1

公开(公告)日：2009-02-19

申请号：US12220374

申请日：2008-07-24

申请人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

发明人： Diana Shu-Lian Chow ,  Pranav Gupta ,  Yulan Qi ,  Dong Liang

IPC分类号： A61K31/4184

CPC分类号： A61K9/1075 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/4184

摘要： Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%.

摘要翻译： 本文提供了药物递送系统，例如适合于向对象的肠胃外或口服递送的自 - 纳米乳化药物递送系统，自乳化药物递送系统和胃肠外微乳剂制剂。 药物递送系统可以在微乳液制剂中包含苯并咪唑衍生物，例如甲苯达唑，油，表面活性剂，辅助表面活性剂和偶极非质子溶剂。 还提供了通过使用组合特定乳剂液滴直径的组合物和其中表面活性剂：助表面活性剂的比例来改善治疗病理生理状况期间苯并咪唑衍生物的生物利用度的方法，用于增加苯并咪唑衍生物在肺中的浓度和保留通过 具有约35nm至小于100nm的液滴尺寸的肠胃外可施用的微乳液，并且在通过具有表面活性剂的肠胃外可施用的微乳液的治疗性治疗期间限定苯并咪唑衍生物的溶血安全微乳液：辅助表面活性剂含量为约6％至48％ 。